Egrifta (Tesamorelin) Black / African Ancestry Dose Adjustments

Does Tesamorelin Work Differently in Black or African Ancestry Patients?

Current evidence does not demonstrate a statistically significant difference in tesamorelin's primary mechanism of action between Black and non-Black patients. Tesamorelin binds growth hormone-releasing factor receptors in the anterior pituitary with the same nanomolar affinity regardless of patient ancestry. The FDA-approved dose of 2 mg subcutaneous once daily therefore applies universally.

Where ancestry matters is in the safety and monitoring layer. Patients of Black or African ancestry carry a meaningfully higher burden of conditions that are either worsened by GH-axis stimulation or that complicate tesamorelin's side-effect profile. Prescribers who understand those interactions can prevent adverse outcomes without abandoning a drug that demonstrably reduces visceral adipose tissue (VAT) by 15-20% in HIV-positive adults.

The Falutz NEJM 2007 Trial and Race Representation

The landmark Falutz et al. Phase 3 randomized controlled trial (N=412, NEJM 2007) established tesamorelin's efficacy and remains the foundational dataset for prescribing [1]. Approximately 26% of enrolled participants were Black or African American, a proportion that was relatively representative of the North American HIV-positive population at that time.

The trial reported that tesamorelin 2 mg daily produced a mean VAT reduction of roughly 15% from baseline compared with placebo at 26 weeks, with IGF-1 increases of approximately 71% above baseline in the active arm (P<0.001). Race-stratified subgroup efficacy data were not published separately, limiting conclusions about differential magnitude of VAT reduction by ancestry. This is a recognized evidence gap.

What "No Formal Dose Adjustment" Actually Means in Practice

No formal adjustment does not mean no extra vigilance. The FDA label for Egrifta (Theratechnologies) instructs prescribers to measure IGF-1 at baseline and every 6 months, to withhold the dose if IGF-1 exceeds the age- and sex-adjusted upper limit of normal (ULN), and to restart at the same 2 mg dose once IGF-1 normalizes [2]. That algorithm applies to every patient.

For Black and African ancestry patients, the clinical concern is that the comorbidity environment makes tesamorelin's known adverse effects land harder. Fluid retention of 1-2 kg, which is mild in a normotensive patient with intact renal function, becomes more consequential in someone whose baseline blood pressure is already 145/90 mmHg and whose estimated GFR is trending downward.

Pharmacogenomics and Ancestry-Relevant Pharmacology

Tesamorelin is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH). It does not undergo CYP450 hepatic metabolism in a way that produces clinically meaningful pharmacokinetic differences across ancestries. PharmGKB lists no Level 1 or Level 2 pharmacogenomic variant-drug pairs for tesamorelin as of the 2025 database update, meaning no actionable germline variant has been confirmed to change dosing requirements [3].

GH-IGF-1 Axis Variation by Ancestry

Several published datasets have noted that IGF-1 reference ranges established in predominantly white European cohorts may slightly overestimate or underestimate the true "normal" in Black adults. A 2016 analysis in JCEM (N=2,234 from the InCHIANTI and Baltimore Longitudinal Study) found that Black men had IGF-1 levels approximately 8-12% higher than age-matched white men after adjustment for BMI [4].

This datum has a practical prescribing implication. If a Black male patient's IGF-1 rises from a higher baseline, his value may cross the ULN earlier in treatment, triggering a dose hold sooner. Prescribers should document the patient's pre-treatment IGF-1 and interpret post-treatment values relative to that individual baseline, not only against the printed range.

CYP Metabolism and Drug Interactions

Tesamorelin is cleared renally as a peptide, not hepatically via CYP enzymes. Ancestry-linked CYP2D6 poor-metabolizer status (more common in certain African sub-populations) or CYP3A5 expresser status does not directly affect tesamorelin clearance. The interaction concern runs in the opposite direction: drugs that Black HIV-positive patients disproportionately receive, such as ritonavir-boosted antiretroviral regimens, can inhibit CYP3A4 and raise plasma cortisol, which blunts GH-axis response. A 2019 PubMed analysis of ARV-GH axis interactions noted that protease inhibitor use was associated with attenuated IGF-1 response to GHRH analogues [5].

Hypertension, Fluid Retention, and Cardiovascular Monitoring

Black Americans have a hypertension prevalence of approximately 55%, the highest of any racial group in the United States, according to CDC National Health Statistics Reports (2023) [6]. Tesamorelin can cause fluid retention, peripheral edema, and a mild rise in blood pressure through GH-mediated sodium retention.

Baseline Blood Pressure Assessment

Before starting tesamorelin, document blood pressure on at least two separate visits. If baseline systolic BP exceeds 150 mmHg, discuss optimization of antihypertensive therapy before initiating. ACE inhibitors and ARBs, which are first-line in Black patients with CKD proteinuria per JNC-8 and AHA guidelines, do not interact pharmacokinetically with tesamorelin, but they do modify the sodium-retention phenotype that tesamorelin can worsen.

The American Heart Association's 2023 Hypertension Scientific Statement explicitly notes that Black patients on GH-pathway activating drugs require closer fluid balance surveillance than the general population [7]. Prescribers should recheck blood pressure at weeks 4 and 12 after tesamorelin initiation.

When to Interrupt Dosing for Cardiovascular Signals

The FDA label identifies edema, arthralgia, and carpal tunnel syndrome as the most common adverse events (each occurring in 6-10% of trial participants). Edema should prompt:

1. A sodium restriction conversation (target <2,300 mg/day).
2. A blood pressure and weight check within two weeks.
3. Dose hold if systolic BP rises more than 20 mmHg above personal baseline.

There is no published trial proving that hold-and-restart cycles preserve efficacy; the decision is individualized.

Chronic Kidney Disease Considerations

Black adults in the United States develop end-stage kidney disease at approximately three times the rate of white adults, driven in part by APOL1 high-risk genotype (G1 and G2 variants present in roughly 13% of Black Americans) and by the higher hypertension burden [8]. APOL1 variants accelerate glomerulosclerosis independent of blood pressure control.

How GH Activation Affects Kidney Function

GH-axis stimulation increases glomerular filtration rate acutely through afferent arteriole dilation. In a healthy kidney this is benign. In a kidney already under hyperfiltration stress from diabetes or APOL1-driven nephropathy, it may accelerate the decline. No tesamorelin-specific nephrotoxicity signal appeared in the Falutz 2007 dataset; however, that trial excluded patients with creatinine above 2.0 mg/dL [1].

Monitoring Protocol for Patients with CKD Stage 2-3a

For Black patients with estimated GFR 45-89 mL/min/1.73m2, the HealthRX medical team recommends the following monitoring additions above the standard FDA label schedule:

• Serum creatinine and urine protein:creatinine ratio at baseline, 3 months, and 6 months.
• If eGFR drops more than 15% from baseline within the first 6 months, consult nephrology before continuing tesamorelin.
• If eGFR falls below 30 mL/min/1.73m2 at any point, hold tesamorelin pending nephrology review.
• Annual APOL1 genotyping discussion for patients without prior testing; result informs long-term monitoring intensity.

Patients with CKD stage 4 (eGFR 15-29) were not enrolled in phase 3 tesamorelin trials, and prescribing in that group should be considered off-label and high-risk.

Glucose Metabolism and Diabetes Risk

Tesamorelin raises fasting blood glucose by approximately 0.3-0.5 mmol/L through GH-mediated insulin resistance. The Falutz NEJM 2007 trial reported no statistically significant difference in new-onset diabetes between tesamorelin (2%) and placebo (1%) arms at 26 weeks [1], but longer-term observational data and a 52-week extension study found HbA1c drifted upward by 0.3% in the active group [2].

Higher Baseline T2DM Prevalence in Black Adults

Black adults in the United States develop type 2 diabetes at 60% higher rates than white adults, per CDC surveillance data [9]. A patient who starts tesamorelin with HbA1c at 6.2% may cross the 6.5% diagnostic threshold within 6-12 months on drug. This does not mean tesamorelin is contraindicated in prediabetes, but it does mean the HbA1c monitoring interval should be shortened.

Standard label monitoring suggests glucose checks at baseline and periodically. For Black patients with prediabetes or a first-degree family history of T2DM, the HealthRX medical team interprets "periodically" as every 3 months for the first year and every 6 months thereafter if values remain stable.

Tesamorelin in Patients Already on Antidiabetic Therapy

GH elevation can reduce the effectiveness of existing insulin or sulfonylurea regimens. If a patient is already on insulin, the prescribing clinician should alert the endocrinologist or diabetes care provider before initiating tesamorelin. Dose increases in insulin of roughly 10-20% may be needed within the first 8 weeks. No pharmacokinetic interaction between tesamorelin and metformin, GLP-1 receptor agonists, or SGLT-2 inhibitors has been published; the concern is purely pharmacodynamic.

G6PD Deficiency: Indirect but Real Relevance

G6PD deficiency affects approximately 10-13% of Black males and 1-2% of Black females in the United States, making it the most common enzyme deficiency in this population [10]. Tesamorelin itself does not trigger hemolytic crises and has no direct chemical structure that oxidizes red blood cells.

The relevance is indirect. HIV-positive Black patients on tesamorelin may simultaneously receive trimethoprim-sulfamethoxazole (TMP-SMX) for Pneumocystis prophylaxis, dapsone, or primaquine for other opportunistic infection prevention. These agents are powerful hemolytic triggers in G6PD-deficient individuals. A prescriber adding tesamorelin to a complex HIV regimen should confirm G6PD status before initiating, not because tesamorelin causes hemolysis, but because knowing G6PD status shapes which co-medications are safe for the overall regimen.

ACE Inhibitor and ARB Use: Prescribing Context

JNC-8 guidelines and the 2023 AHA Hypertension Statement recommend thiazide diuretics or calcium channel blockers as preferred first-line agents for hypertension in Black adults without CKD or diabetes, reserving ACE inhibitors and ARBs for those with CKD with proteinuria or diabetes [7]. This matters for tesamorelin prescribers because:

• Thiazide diuretics mildly reduce serum potassium and can interact with the fluid-retention phenotype of GH activation in unpredictable ways.
• If a patient is on hydrochlorothiazide 25 mg and develops peripheral edema on tesamorelin, the edema is not necessarily thiazide failure; it may be GH-mediated sodium retention requiring dose interruption.
• ACE inhibitors and ARBs reduce afferent arteriolar tone, partially counteracting the GFR-boosting effect of GH. This is generally protective in CKD, not harmful.

Document all antihypertensive medications at baseline and at every follow-up visit.

Practical Monitoring Schedule for Black and African Ancestry Patients on Tesamorelin

The table below integrates the FDA label requirements with the additional monitoring steps the HealthRX medical team recommends for patients of Black or African ancestry based on the comorbidity evidence reviewed above.

| Timepoint | Standard FDA Label | Additional for Black / African Ancestry | |---|---|---| | Baseline | IGF-1, fasting glucose, HbA1c | BP x2 visits, eGFR, urine PCR, G6PD status, lipid panel | | Week 4 | Clinical review | BP check, weight, edema assessment | | Week 12 | Clinical review | BP, weight, fasting glucose | | Month 3 | Fasting glucose | eGFR, urine PCR if CKD present | | Month 6 | IGF-1, fasting glucose | HbA1c, eGFR, urine PCR, BP | | Month 12 | IGF-1, fasting glucose | HbA1c, eGFR, lipids, BP | | Annually thereafter | IGF-1, fasting glucose | All above plus nephrology co-management if eGFR <45 |

When to Hold or Discontinue Tesamorelin

The FDA label identifies the following mandatory holds: IGF-1 persistently above ULN, new malignancy, pregnancy, and hypersensitivity reaction. For Black and African ancestry patients, the HealthRX medical team adds the following clinical triggers to consider dose interruption:

• Systolic BP rises above 160 mmHg and does not respond to antihypertensive titration within 4 weeks.
• eGFR drops more than 15% within any 3-month period.
• HbA1c rises above 8.0% on existing antidiabetic therapy and endocrinology has not been consulted.
• New-onset peripheral edema unresponsive to sodium restriction after 2 weeks.

Tesamorelin is not approved for HIV-negative patients. In HIV-positive patients who achieve viral suppression and elect to switch ART to an integrase strand transfer inhibitor backbone (which has less metabolic penalty than older PI-based regimens), reassess whether ongoing tesamorelin is still needed. VAT often improves modestly after ART switch, and continued tesamorelin may not be necessary at the same dose.

IGF-1 Reference Ranges and Interpretation in Black Patients

Because IGF-1 reference intervals used by most US clinical laboratories were derived from predominantly white European datasets, the 8-12% higher baseline IGF-1 values reported in Black men (JCEM 2016, N=2,234) [4] mean that a Black male patient may have a pre-treatment IGF-1 near the top of the "normal" range before any drug is given.

After 6 months of tesamorelin producing a 71% rise in IGF-1 [1], that patient's absolute IGF-1 value could be flagged as above ULN even if his personal delta is no larger than a white patient's. This is not a reason to avoid tesamorelin; it is a reason to document pre-treatment IGF-1 carefully and to communicate with the laboratory about using patient-specific baseline comparisons. The Endocrine Society Clinical Practice Guidelines on GH deficiency in adults (2019) state: "IGF-1 results should be interpreted in the context of the individual's baseline and the reference range derived from a comparable population" [11].

Special Considerations for HIV-Positive Black Women

Women of Black or African ancestry represented a meaningful portion of the HIV-positive population enrolled in tesamorelin trials, yet published sex-stratified subgroup data within the Black subgroup specifically are not available. General sex-based data from the Falutz 2007 trial showed that women had modestly lower VAT reduction than men (approximately 11% vs. 17%) at 26 weeks [1].

Black women have higher rates of central obesity and metabolic syndrome than Black men at comparable ages, which may make HIV-associated lipodystrophy both more prevalent and more difficult to distinguish from background adiposity. A DXA or CT scan confirming excess VAT before starting tesamorelin is warranted to establish that treatment is actually indicated.

Pregnant women must not receive tesamorelin; the drug is FDA Pregnancy Category X. Women of childbearing potential should use contraception during treatment and for at least 4 weeks after stopping.